Research advances on anti-ANGPT2 antibody in acute myeloid leukemia.
10.7534/j.issn.1009-2137.2014.05.052
- Author:
Yan-Wei CHEN
1
;
Hong YANG
1
;
Hong MOU
1
;
Song-Lan YANG
1
;
You ZHANG
2
Author Information
1. Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650500, Yunnan Province, China.
2. Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650500, Yunnan Province, China. E-mail: youzhangmd@ailyun.com.
- Publication Type:Journal Article
- MeSH:
Angiopoietin-1;
immunology;
Antibodies;
immunology;
Bone Marrow;
Humans;
Leukemia, Myeloid, Acute;
immunology;
Neoplasm Invasiveness;
Neoplasm Metastasis
- From:
Journal of Experimental Hematology
2014;22(5):1459-1462
- CountryChina
- Language:Chinese
-
Abstract:
Angiopoietin2( ANGPT2 ) plays an important role in tumor angiopoiesis. ANGPT2 antagonises ANGPT1 resulting in an effect on the stability of blood vessels, which promotes tumor growth, invasion, proliferation as well as relating to tumor vascular density. A lot of researches published papers about anti-ANGPT2 for the treatment of tumor, and have made some progresses. In this review, the role of ANGPT2 in the pathogenesis of acute myelogenous leukemia (AML), including its effects on proliferation of leukemia cells, bone marrow angiopoiesis, tumor invasion and metastasis are briefly summarised in order to provide the basis for targeted ANGPT2 in treatment of AML.
